News 12.01.2026 Schlieren / Zurich, Switzerland, 9 January, 2026 – Memo Therapeutics AG (“MTx”), a late-stage biotech company translating unique human immune responses into superior medicines to treat viral infections and cancer, today announces the publication of a qualitative research paper titled ‘Development of a Conceptual Model of BKV Impacts on Health-Related Quality of Life...
News 12.01.2026 ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Jan. 11, 2026 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a novel class of protein drugs known as DARPin therapeutics (“Molecular Partners” or the “Company”), today provided an update...
News 09.01.2026 SCHLIEREN, Switzerland--(BUSINESS WIRE)--Virometix AG, a clinical-stage biotechnology company pioneering fully synthetic vaccines, today announced positive topline data from the Company’s Phase 1 trial of its lead asset V-212, a serotype-independent pneumococcal vaccine candidate, in development for the prevention of pneumococcal disease caused by Streptococcus pneumoniae (Spn) infections. The study evaluated safety and...
News 07.01.2026 At the interface of MedTech and Pharma, hemotune AG is engineering a world‑leading magnetic nanoparticle platform to transform separation across the medical value chain – and beyond. 📢 Today, we are delighted to announce that Christian Brühlmann has joined hemotune as Chief Business Officer. With this appointment, our C‑level expands to...
News 07.01.2026 Cologne, Germany, January 7, 2026 – DISCO Pharmaceuticals (“DISCO”), today announced an exclusive license agreement with Amgen to advance novel therapeutic candidates addressing a target that was mapped on the surface of a cancer cell by DISCO’s proprietary platform. Under the terms of the agreement, DISCO will be eligible to receive up...